Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation - Wikidata - awgldk - TriplyDB

Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation

Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation

http://www.wikidata.org/entity/Q36673709

about

Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants Inhibition of STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian cancer cells Reovirus in cancer therapy: an evidence-based review Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma Resveratrol and STAT inhibitor enhance autophagy in ovarian cancer cells.Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.Oncolytic virus-mediated reversal of impaired tumor antigen presentation.Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.The oncolytic virus, pelareorep, as a novel anticancer agent: a review.Arming oncolytic viruses to leverage antitumor immunity.Intraperitoneal immunotherapy: historical perspectives and modern therapy.Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses.Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.Panorama from the oncolytic virotherapy summit.Immunotherapy for ovarian cancer: what are the targets of the future?Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis

P2860

Q26775033-4FFC331E-D7FD-4111-9DA4-E912184CE28B Q35538822-A04916D9-A0D7-40D6-AA22-7BE8E8BB61CF Q37031909-FE34AE69-85A4-4492-B927-1003E6D7CE67 Q37043514-1CB1BE1A-3507-43B5-BBDF-0A67AFDF1C85 Q37164378-1C208C5A-0EF1-4146-B348-4DDBBF0BE8BE Q37459636-92C4CBA2-8D93-494B-A609-ECDC1FE75C91 Q38208315-72E42A5F-6385-423F-B379-1BA5995E5FDA Q38241666-6A9180BC-AD40-4C66-BD08-A51358BC8D99 Q38360781-5675E54F-D158-4610-ACC5-79F28385F884 Q38470166-F6E62B13-C64F-47CF-979B-7994EC772263 Q39005211-924BA48F-6DB3-4E37-B7B8-C702A1B1106E Q39244891-67276DD7-5C87-410E-B41D-41A6651DFED5 Q41137180-B5B96636-7659-4376-86EA-AC6E26C92D1E Q42934744-61304215-599C-4D10-9330-EE5200A25D31 Q48489326-31BA9BAC-29B6-4A10-B41A-A0C92F32FD26 Q52769260-0FC7E787-E40C-4485-8E34-1BA642C6D086 Q57300017-AD5F5DF9-353C-4976-94C5-4A537EFE6EF3 Q58788761-C2F67E08-4B14-471C-B156-F9137F729695

P2860

Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation

http://www.wikidata.org/entity/Q36673709

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Multifaceted therapeutic targe ...... virus-induced immunomodulation

@ast

Multifaceted therapeutic targe ...... virus-induced immunomodulation

@en

type

label

Multifaceted therapeutic targe ...... virus-induced immunomodulation

@ast

Multifaceted therapeutic targe ...... virus-induced immunomodulation

@en

prefLabel

Multifaceted therapeutic targe ...... virus-induced immunomodulation

@ast

Multifaceted therapeutic targe ...... virus-induced immunomodulation

@en

P1433

Q36673709-1C84CE7C-6155-4AE0-ACB4-380CEBAE8097

P1476

Q36673709-B247AE27-839A-41B2-AD2D-7C8F0DB8049B

P2093

Q36673709-29103FD0-9165-49A1-9FA7-D122EED6AA0A

Q36673709-423DD31F-B460-4EA6-A3A9-0DB4E392676D

Q36673709-56F2746B-0AD1-47A3-8A04-B33E78C0D535

Q36673709-63A29BEF-97F3-418A-B4C0-D69501C5EA74

Q36673709-701F0A16-2836-49A1-99B1-BDB35E3C7571

Q36673709-7EE93423-5ECB-4AE5-ADC7-1670C426C758

Q36673709-8499C267-C453-441A-A743-5AF8FAC1B185

Q36673709-B1E7EA34-8B69-41A1-96C5-2E1DAD6A9BE0

Q36673709-CF5AB8BF-4E0F-4C41-B228-107B5EC7D254

Q36673709-FA2965CF-D29F-4821-9E52-9D70E6A17C30

P2860

Q36673709-11AA42E9-49D7-4A6D-A9F1-721B421ACDCA

Q36673709-1A220C79-BF26-4517-AC15-CFFD7370E6D6

Q36673709-220EB650-3837-4F2A-BA3C-5261833E4F76

Q36673709-2777C801-848B-457E-A9A4-E9B690DBA294

Q36673709-32311BAC-4A5F-4318-A41F-094D273E19DF

Q36673709-352936B0-B341-4A2F-82F3-E78349E32DD6

Q36673709-379022F9-5A15-477A-9390-214ECAB5AF00

Q36673709-3E931832-5858-457D-98D0-8274E033D5B9

Q36673709-426661EA-DC17-45D6-90BF-26AA32893A0C

Q36673709-4576CA4B-250B-46B4-9D6D-C2A0A63225A2

P304

Q36673709-BD8140EE-8BF1-4AF4-B52C-1B7A445F60E9

P31

Q36673709-DB897407-A19F-499F-BD78-449B091ECAED

P356

Q36673709-152324F8-EDE1-44CC-AC12-3F9D2152719D

P433

Q36673709-F150A481-1354-4A5E-9EA6-7C60419F2961

P478

Q36673709-B66CC8EF-9B88-413E-96D6-43E1FF3EC624

P50

Q36673709-6385C08B-C612-41FE-A495-6AD169B684F0

P577

Q36673709-2D389C76-401C-4F3E-BF0D-81F8BE0D34E4

P5875

Q36673709-7F5DC557-DC51-4B24-B22B-D15C21C57C57

P698

Q36673709-54528F58-EC48-45B0-A7B0-C329AAD7043B

P932

Q36673709-3A2B255E-33DA-4348-A249-EA01939E44F8

P356

P1433

Molecular Therapy

P1476

Multifaceted therapeutic targe ...... virus-induced immunomodulation

@en

P2093

Abdulaziz Alawadhi

http://www.w3.org/2001/XMLSchema#string

Da Pan

http://www.w3.org/2001/XMLSchema#string

Derek Clements

http://www.w3.org/2001/XMLSchema#string

Erin Helson

http://www.w3.org/2001/XMLSchema#string

Lu-Zhe Pan

http://www.w3.org/2001/XMLSchema#string

Maya Shmulevitz

http://www.w3.org/2001/XMLSchema#string

Paola Marcato

http://www.w3.org/2001/XMLSchema#string

Patrick W K Lee

http://www.w3.org/2001/XMLSchema#string

Rebecca Dielschneider

http://www.w3.org/2001/XMLSchema#string

Shashi Gujar

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

Omental immune aggregates and tumor metastasis within the peritoneal cavity.

A phase 3 trial of bevacizumab in ovarian cancer.

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.

Reovirus therapy of tumors with activated Ras pathway.

Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.

HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma

Regulatory T cells in ovarian cancer: biology and therapeutic potential.

P304

338-347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2012.228

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234089435

http://www.w3.org/2001/XMLSchema#string

P698

23299799

http://www.w3.org/2001/XMLSchema#string

P932

3594021

http://www.w3.org/2001/XMLSchema#string